Month: July 2024

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province People's Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.

On July 14, the "8th Yunnan Breast Cancer Summit Forum" was held in Kunming, coinciding with the 40th anniversary of the Yunnan Cancer Hospital. This event, organized by the Yunnan Anti-Cancer Association and the China Medical Education Association, and co-hosted by eight institutions including the Peking University Cancer Hospital Yunnan Branch, Yunnan Cancer Hospital, and the Third Affiliated Hospital of Kunming Medical University, brought together the latest advances in breast cancer. At the conference, "Oncology Frontier" invited Dr. Zhaoqing Fan from Peking University Cancer Hospital to provide an overview of the treatment landscape for HR+/HER2- breast cancer and to discuss the prospects of immunotherapy in early-stage patients based on the CheckMate 7FL and KEYNOTE-756 studies, guiding the future direction of new drug development for neoadjuvant therapy.

The development of modern oncology has provided multiple breakthrough treatment options for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians comprehensively grasp the significant advancements in this field, "Oncology Frontier" collaborates with Dr. Hua Zhong and Dr. Baohui Han from the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital, Shanghai JiaoTong University School of Medicine, to present the clinical progress series "Zhong" Sound "Hui" Words. Through high-quality interpretations of clinical research in lung cancer, this series aims to enhance clinical practice. In the 22nd episode, the Dr. present "Evaluation of the Efficacy and Safety of Entrectinib Targeted Therapy for ROS1 Fusion Detected in Peripheral Blood," based on data from the BFAST clinical study's D cohort, recently published in Nature Medicine.

From July 5-7, 2024, the "2024 Annual Progress in Clinical Oncology Conference (BOC) and Best of ASCO® 2024 China (BOC/BOA)" was grandly held in Guangzhou. In the field of breast cancer, this conference highlighted key advancements from the American Society of Clinical Oncology (ASCO) annual meeting, showcasing China's research impact on the international stage. "Oncology Frontier" interviewed Dr. Qiang Liu, host of the breast cancer session and from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to share session highlights and impacts, pointing out future trends in breast cancer treatment development.

On July 12-13, the 2024 CACA Integrated Breast Cancer Conference was held in Kunming, hosted by the Chinese Anti-Cancer Association (CACA) and the CACA Integrated Breast Cancer Committee, and organized by the China Academy of Integrated Medicine and Strategy Development, Yunnan Cancer Hospital, and ten professional committees. "Oncology Frontier" invited Dr. Jiong Wu, Chairman of the conference and from Fudan University Shanghai Cancer Center, to elaborate on the concept of "Winning in Integration for Tumor Prevention and Treatment." He discussed the challenges in breast cancer treatment under the integrated medicine philosophy and shared suggestions for better implementation of integrated breast cancer treatment in primary healthcare institutions.

The "2024 CACA Integrated Breast Cancer Conference," hosted by the Chinese Anti-Cancer Association and the Chinese Anti-Cancer Association's Breast Cancer Committee, was held in Kunming, Yunnan, from July 12-13, 2024. The conference, under the theme "Cancer Prevention and Treatment: Winning Through Integration," focused on new concepts, knowledge, and technologies in breast cancer diagnosis and treatment, discussing strategies for precise and standardized treatment. During the event, the 10th Committee of the Chinese Anti-Cancer Association's Breast Cancer Professional Committee (referred to as the Committee) was elected. Dr. Jin Zhang from Tianjin Medical University Cancer Institute and Hospital was elected as the Chair of the 10th Committee. In an interview, Professor Zhang shared her vision for the future work of the Committee and her insights on integrating breast cancer prevention and treatment efforts.

With the continuous advancement of cancer treatment technologies, the survival rate of cancer patients has significantly improved, but the issue of cardiac safety during antitumor therapy has increasingly become a clinical focus. In this context, cardio-oncology has emerged as an important interdisciplinary field. At the "2024 CACA Integrated Breast Cancer Conference," during the breast cancer integration and rehabilitation session, Dr. Fengqi Fang from The First Affiliated Hospital of Dalian Medical University shared her insights on "Cardiac Safety Management in Antitumor Therapy for Breast Cancer." After the session, "Oncology Frontier" interviewed Professor Fang on the latest research and future directions in cardio-oncology.

At the 2024 ASCO Conference, the progress in breast cancer ADC (antibody-drug conjugate) research was remarkable. T-DXd demonstrated excellent efficacy in HER2-positive breast cancer, significantly extending patient survival and reinforcing the concept of using the best drugs first. In HR-positive and triple-negative breast cancer, Dato-DXd showed good safety and efficacy, laying the foundation for future combination therapy regimens. Additionally, domestic ADC drugs like ARX788 and SKB264 provided new treatment options for breast cancer patients. In this article, Dr. Songqing Ye from Fujian Provincial Hospital provides an in-depth analysis of the latest research findings on ADC drugs in HER2-positive, HR-positive, and triple-negative breast cancer presented at the 2024 ASCO Conference.